Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 75,000 shares at $1.43 ($106K) on 2015-09-29, disclosed to the SEC on 2015-10-01.
Open-market sale of $106k CTIC by EVP, Corporate Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.41 | 52,306 | $74K | 69.5% |
| 2 | $1.42 | 5,108 | $7K | 6.8% |
| 3 | $1.42 | 9,092 | $13K | 12.2% |
| 4 | $1.43 | 100 | $143 | 0.1% |
| 5 | $1.43 | 8,394 | $12K | 11.3% |
| Total | $1.41 avg | 75,000 |
| $106K |
| 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |